Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ERK 1/2 inhibitor ASTX029

An orally bioavailable inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. Upon administration, ASTX029 specifically binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in the proliferation, differentiation and survival of tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ERK inhibitor ASTX029
extracellular signal-regulated kinase 1/2 inhibitor ASTX029
extracellular signal-regulated kinase inhibitor ASTX029
Code name:ASTX 029
ASTX-029
ASTX029
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search